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Abstract
Background: Chronic Kidney Disease (CKD) is a major global health problem. CKD is one of the most common
complications of diabetes mellitus and hypertension and carries a risk of cardiovascular morbidity and mortality and
progression to end-stage kidney disease.
Objectives: This study sought to use the 2012 Kidney Disease Improving Global Outcomes (KDIGO) definitions to
establish the prevalence and risk factors for CKD among a high risk population in the Sekondi-Takoradi metropolis.
Design: Cross sectional study.
Setting: Effia-Nkwanta regional and the Takoradi Government hospitals in South Western Ghana.
Patients: Two hundred eight consecutive adults with diabetes, hypertension or both.
Measurements: Serum creatinine and urine albumin-creatinine ratio respectively. The Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) was used to estimate glomerular filtration rate (GFR).
Methods: CKD was classified according to KDIGO.
Results: The prevalence of CKD was 30 %: 27 % in patients with diabetes, 22 % in patients with hypertension only
and 74 % in patients with both diabetes and hypertension. GFR category G3a CKD was most prevalent stage (9 %).
Albuminuria was highest among people with diabetes (39 %).
Limitations: A convenience sample of patients attending clinics.
Conclusion: CKD was prevalent in these high-risk patients.
Abrégé
Contexte: L’insuffisance rénale chronique (IRC) est un problème majeur de santé globale. Elle se révèle l’une des
plus fréquentes complications du diabète sucré et de l’hypertension. De plus, l’IRC pose un risque accru pour les
patients de souffrir, voire de mourir de cardiopathie, ou alors de voir leur état progresser vers l’insuffisance rénale
terminale.
Objectifs de l’étude: L’étude a cherché à établir la prévalence et les facteurs de risque de l’IRC dans la population
prédisposée de la métropole de Sekondi-Takoradi (Ghana) en utilisant les définitions proposées par « Kidney
Disease Improving Global Outcomes » (KDIGO) en 2012.
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Type d’étude: Il s’agit d’une étude transversale.
Contexte de l’étude: L’étude a été effectuée sur des patients de l’hôpital régional Effia-Nkwanta et de l’hôpital
gouvernemental de Takoradi, dans le sud-ouest du Ghana.
Patients: L’étude était constituée d’une cohorte de 208 adultes atteints de diabète, d’hypertension ou d’une
comorbidité.
Mesures: Le rapport albumine-créatinine dans l’urine ainsi que le taux de créatinine sérique ont été mesurés, puis
le débit de filtration glomérulaire (GFR) a été déterminé à l’aide de l’équation du « Chronic Kidney Disease
Epidemiology Collaboration » (CKD-EPI).
Méthodologie: L’IRC a été déterminée selon les critères de KDIGO.
Résultats: À la suite de cette étude, la prévalence d’IRC a été établie à 30 % parmi les patients de la cohorte. Elle
s’établissait à 27 % chez les patients atteints de diabète seulement, 22 % chez les patients atteints d’hypertension
seulement et de 74 % chez les patients présentant à la fois du diabète et de l’hypertension. Le stade d’IRC (9 %) le
plus prévalent était de catégorie G3a. La prévalence d’albuminurie était plus élevée chez les patients diabétiques
(39 %).
Limites de l’étude: Il s’agit d’un échantillon de commodité formé de patients fréquentant les deux cliniques
mentionnées plus haut.
Conclusions: La prévalence d’insuffisance rénale chronique était plus élevée chez ce groupe de patients considérés
à haut risque.
Background
Chronic Kidney Disease (CKD) is defined as abnormal-
ities of kidney structure or function, present for more
than 3 months, with implications for health [1, 2]. It is
characterized by either decreased glomerular filtration
rate (GFR) or albuminuria, or both, and carries a risk of
cardiovascular morbidity and mortality and progression
to end-stage renal disease (ESRD) [3]. Chronic kidney
disease is thought to be prevalent in sub-Saharan Africa
and to be a major public health problem [4]. Resources
for recognition and management aiming at reduction in
progression are limited, and resources for the treatment
of ESRD severely limited [4].
Chronic kidney disease (CKD) is one of the most com-
mon complications of diabetes mellitus [5] and hyperten-
sion [5]. Screening for CKD is not routinely performed in
many diabetic clinics in sub-Saharan Africa because of
limited human resource, diagnostic facilities and the cost
of the tests [5–7].
Several studies within sub-Saharan Africa have exam-
ined the prevalence of CKD in people at high risk, includ-
ing those with diabetes and hypertension. Janmohamed et
al., [7] recorded 84 % prevalence in adult outpatients with
diabetes in Tanzania, and Osafo et al. [8] showed a CKD
prevalence of 47 % among Ghanaian patients, mainly from
the Greater Accra region, with hypertension. In addition,
Sumaili et al., [9] recorded 44 % prevalence in patients
with hypertension, 39 % in those with diabetes; 16 % in
people with obesity and 12 % in those who had human
immunodeficiency virus (HIV) or acquired immunodefi-
ciency syndrome (AIDS). We used the 2012 guidelines of
the kidney disease improving global outcomes (KDIGO)
to classify CKD among patients with diabetes, hyperten-
sion and both and also identified the associated risk fac-
tors for CKD in the Sekondi-Takoradi metropolis in south
western Ghana.
Methods
Study design and study site
A cross-sectional study was conducted at the outpatient
diabetes and hypertension clinics of the Effia-Nkwanta
Regional hospital (ERH) and the Takoradi Government
Hospital (TGH) in the Sekondi-Takoradi metropolis be-
tween December 2012 and May 2013. These serve as the
major healthcare facilities in the metropolis providing
primary, secondary and tertiary healthcare services for a
population of 445,000. The healthcare system is access-
ible to those who contribute or pay the minimum of GH
20.0 yearly premium, equivalent to about three times the
daily minimum wage of GH 6.0; about 66 % of the popu-
lation is covered. In Ghana, patients with diabetes or
hypertension receive specialized care in teaching, regional
or municipal hospitals since they are the only facilities
with the capacity to diagnose and manage this condition.
Sekondi-Takoradi is the administrative capital of the
Western Region. It has a land area of 385 km2 and is
located in the South-Western part of Ghana and about
242 km west of Accra, the capital city of Ghana.
Inclusion and exclusion criteria
We enrolled eligible adult (>18 years) outpatients receiv-
ing medical care at the diabetes and hypertension clinics
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of the hospitals during the study period. Patients diag-
nosed with high blood pressure or on anti-hypertensive
drugs, diabetes or both hypertension and diabetes were
included in this study. We excluded patients with other
kidney diseases (such as glomerulonephritis, vasculitis,
kidney infection, connective tissue disease or adult poly-
cystic kidney disease), those undergoing peritoneal or
hemodialysis, and those with inflammatory bowel dis-
ease or rheumatoid arthritis. We also excluded people
with known hepatitis B or C and HIV/AIDS.
Patient screening, recruitment and data collection
We screened 382 consecutive patients with diabetes,
hypertension or both who visited the outpatient depart-
ment of the two hospitals for routine evaluation. Dia-
betes was defined as a diagnosis of diabetes or taking a
hypoglycaemic drug, and hypertension as a diagnosis of
hypertension or taking an anti-hypertensive drug. Infor-
mation on age, gender, fasting blood glucose, body mass
index (BMI), systolic blood pressure and diastolic blood
pressure, medication used, duration on medication, and
duration of diabetes was obtained using a pre-tested ques-
tionnaire and the patient medical records.
Measurement of blood pressure
Trained personnel used a mercury sphygmomanometer
(ACCOSON, England) with a standard or a large cuff,
appropriate to the patient’s size, to measure blood
pressure after patients rested for 5 min, in accordance
with recommendations of the American Heart Associ-
ation Council on High Blood Pressure Research [10].
We report mean values of duplicate measurements.
Fig. 2 Medications used by participants with diabetes and hypertension
Fig. 1 Types of medications used by participants
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Body mass index (BMI)
Height (nearest centimetre) and weight (nearest 0.1 kg),
without shoes and in light clothing were measured. Par-
ticipants were weighed on a bathroom scale (Zhongshan
Camry Electronic Co. Ltd, Guangdong, China) and their
height measured with a wall-mounted ruler. BMI was
calculated by dividing weight (kg) by height squared
(m2), and categorized according to WHO criteria into
normal weight (BMI 18.5–24.9), underweight (<18.5),
overweight (25.0–29.9), obese (30.0–39.9) [11].
Blood sample collection and processing
A 4 ml venous blood sample was collected from each
participant and 1 and 3 ml were dispensed into a fluoride
oxalate tube and a serum gel separator tube respectively.
After centrifugation at 1500 g for 3 min, the plasma and
serum were stored in cryovials at −80 °C until assays were
performed.
Biochemical analysis
Plasma fasting blood sugar (FBS), serum urea and creatin-
ine were estimated using automated chemistry analyzer
(Selectra JR). Estimated glomerular filtration rate (eGFR)
was calculated using the CKD-EPI equation using the
coefficients for black ethnicity in all [12].
Urine sample collection and processing
Urine protein was quantitatively estimated using the
method of [13]. Estimation of urine creatinine was done
using automated analyzer (ENVOY500/BT 3000 chemis-
try analyzer. Urine protein-creatinine ratio (uPCR) was
calculated by the following formula: uPCR (mg/mmol =
urine protein (mg/dl)/urine creatinine (mmol/dl). The
urine protein/creatinine ratio (uPCR) was reported as mg/
mmol. Resources were not available to measure albumin-
uria. The relationship between uACR and uPCR is not a
simple one, so we did not attempt to convert between the
two [14]. Instead we report uPCR in uACR categories,
recognizing that this leads to overestimation of the
proportions of patients with problems.
Statistical analysis
Analysis was performed using Graphpad prism version
5.0 (GraphPad software, San Diego California USA,
www.graphpad.com). Two-sample Student’s t test and
chi-squared or Fisher’s exact test, as appropriate, and
one-way analysis of variance (ANOVA) were used to
compare groups. A P-value ≤0.05 was considered statisti-
cally significant.
Ethical considerations
The study was approved by the University of Cape Coast
institutional review board (UCC/IRB) and the committee
of ethics of TGH and ERH. Written informed consent
was obtained from all participants.
Funding
Study procedures including collection of clinical data
and the laboratory tests were funded by the authors.
Results
We screened 382 consecutive patients, of whom 76 were
less than 18 years, and 67 declined to participate: of the
239 consenting participants, 208 provided both blood
and urine samples (i.e., 87 % with complete data) and
are the subject of this report. Mean age was 60 and 71 %
were female (Table 1); blood pressure was higher in par-
ticipants with known hypertension. The distribution of
body weight did not vary with diagnosis (diabetes,
Table 1 Demographic, clinical and biochemical characteristics






diabetes (n = 23)
P-value
Age (years) 60.2 ± 10.1 60.8 ± 9.5 60.7 ± 8.6 0.913
Age group (years)
< 40 5 (4.2) 1 (1.5) 0 (0.0)
40–49 11 (9.2) 8 (12.3) 1 (4.3)
50–59 38 (31.7) 16 (24.6) 9 (39.1)
60–69 44 (36.7) 27 (41.5) 9 (39.1)
≥ 70 22 (18.3) 13 (20.0) 4 (17.4)
Sex
Male 32 (26.7) 21 (32.3) 7 (30.4)
Female 88 (73.3) 44 (67.7) 16 (69.6) 0.795
Disease Duration
(years)
5.4 ± 2.4 5.2 ± 2.3 6.3 ± 3.4 0.192
Disease Duration Category
< 5 51 (42.5) 30 (46.2) 8 (34.8)
5–10 65 (54.2) 32 (49.2) 13 (56.5)
> 10 4 (3.3) 3 (4.6) 2 (8.7) 0.721
FBG (mmol/l) 9.7 ± 3.7 5.8 ± 1.4 13.4 ± 4.7 <0.001
SBP (mmHg) 130.3 ±
15.1
145.7 ± 22.8 160.0 ± 17.8 <0.001
DBP (mmHg) 75.1 ± 8.7 85.2 ± 10.2 94.8 ± 12.0 <0.001
BMI (kg/m2) 27.5 ± 5.2 27.4 ± 5.0 27.7 ± 5.6 0.966
BMI Category n(%)
Underweight 3 (2.5) 1 (1.5) 0 (0.0)
Normal 34 (28.3) 19 (29.2) 10 (43.5)
Overweight 48 (40.0) 29 (44.6) 6 (26.1)
Obese 35 (29.2) 16 (24.6) 7 (30.4) 0.672
eGFR,
mL/min/1.73 m2
82 ± 32 76 ± 26 61 ± 39 0.012
FBG fasting blood glucose, BMI body mass index, ACE angiotensin converting
enzyme, eGFR estimated glomerular filtration rate
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hypertension or both) (Table 1). Figures 1 and 2 report
the types of medication used by participants and the
types of medications used by hypertensives and diabetics
respectively.
Overall, 13 of 208 participants (6.2 %) had GFR less
than 30, and 50 (24 %) had eGFR less than 60 mL/min/
1.73 m2 (Table 2); 4 of 40 participants (10 %) had
uPCR > 30 mg/mmol, and 43 (96 %) had uPCR 3–30 mg/
mmol. GFR less than 30 mL/min/1.73 m2 and uPCR > 3
were more prevalent in those with both diabetes and
hypertension than in patients with just one diagnosis
(Table 3). Age and gender were similar across eGFR cat-
egories, but patients with the lowest eGFR had the highest
systolic and diastolic blood pressures, and systolic blood
pressure was above 140 in 17 and 26 % respectively of
those in eGFR categories 3a and 3b, and in 36 % of those
in eGFR category 4 (eGFR less than 30 mL/min/1.73 m2).
Table 3 show the distribution of patients by GFR and
albuminuria categories, for those with hypertension, dia-
betes and both diabetes and hypertension. Overall, 30 %
of participants fell into the category defined by KDIGO
as ‘very high risk’: 23 % of patients with hypertension,
27 % of patients with diabetes and 74 % of those with
both diabetes and hypertension.
Multivariable predictors of the presence of CKD were
diagnosis category and duration on medication, both
with odds ratios around 10, but not age, gender or BMI
(Table 4).
Discussion
We identified a prevalence of CKD in patients with hyper-
tension of 22 % and in patients with diabetes of 27 %. In
patients with both hypertension and diabetes, the preva-
lence was 74 %, and 26 % had category G4 CKD. Clinical
factors associated with a greater risk of CKD were the
presence of both hypertension and diabetes, and duration
on medication (antidiabetic and antihypertensive).
Osafo and colleagues [8] reported a 47 % prevalence of
CKD among patients with hypertension in Ghana, in a
multicenter study conducted predominantly among people
with hypertension in the Greater Accra area (known for a
high prevalence of hypertension). This is higher than the
overall prevalence of 30 % among our study participants,
and 22 % in people with hypertension. The difference may,
in part, be owing to our having used the CKD-Epi [12]
equation rather the MDRD equation, which was used in
the study by Osafo and colleagues. MDRD is known to
overestimate the prevalence of CKD compared with CKD-
Table 2 Prevalence of albuminuria, estimated glomerular filtration rate (eGFR) and stages of CKD stratified by clinical conditions
Variable Diabetes (n = 120) Hypertension (n = 65) Hypertension and diabetes (n = 23) Total (n = 208) P-value
uPCR
<3 mg/mmol 102 (85.0) 52 (80) 7 (30.4) 161 (77.4) p < 0.001
3–30 mg/mmol 18 (15.0) 10 (15.4) 15 (65.2) 43 (20.7)
>30 mg/mmol 0 (0.0) 3 (4.6) 1 (4.3) 4 (1.9)
eGFR, mL/min/1.73 m2 n (%)
≥90 39 (33) 16 (25) 5 (22) 60 (29) p < 0.001
60–89 54 (45) 39 (60) 5 (22) 98 (47)
45–59 15 (13) 1 (1.5) 3 (13) 19 (9.1)
30–44 9 (7.5) 5 (7.7) 4 (17) 18 (8.7)
15–29 3 (2.5) 4 (6.2) 6 (26) 13 (6.2)
<15 0 0.0) 0 (0.0) 0 (0.0) 0 (0.0)
CKD n (%)
Stage 1: eGFR ≥90 + Alb 1 (0.8) 1 (1.5) 1 (4.3) 3 (1.4) 0.16
Stage 2: eGFR 60–89 + Alb 4 (3.3) 3 (4.6) 3 (13.0) 10 (4.8)
Stage 3a: eGFR 45–59 15 (12) 1 (1.5) 3 (13.0) 19 (9.1)
Stage 3b: eGFR 30–44 9 (7.5) 5 (7.7) 4 (17) 18 (8.7)
Stage 4: eGFR15–29 3 (2.5) 4 (6.2) 6 (26) 13 (6.3)
Stage 5: eGFR < 15 0 0 0 0
Total CKD, n (%)
(Stages 1–5) 32 (27) 14 (22) 17 (74) 63 (30)
Note to authors: the reference here should be a citation and should be to the earlier version of the guidelines that used the staging terminology
We include stages as described in earlier KDIGO guidelines (KDIGO 2013) for the purposes of comparison with other studies
uPCR rine protein-creatinine ratio, eGFR estimated GFR, CKD chronic kidney disease
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Epi, and this has also been shown by Kitiyakara and
colleagues in their study of the high risk population in
South East Asia [15]. In all patients with diabetes (with or
without hypertension) we observed a prevalence of 48 %,
which is lower than the 80 % prevalence observed among
African adults with diabetes in a cross-sectional study
conducted in Tanzania by Janmohamed and colleagues
[7]. Again this is not directly comparable, with differences
arising from their use of Cockroft-Gault equation to
calculate the eGFR (which overestimates true GFR and un-
derestimates prevalence); and urine albumin concentration
as a measure of proteinuria (which is the recommended
method of assessing proteinuria; our use of uPCR overesti-
mates prevalence) but both these differences would result
in a tendency for our prevalence by our methods to be
higher than by their methods; so it may be that true differ-
ences exist. However, neither study used IDMS calibrated
creatinine measurement and the direction of biases result-
ing from this limitation cannot be assessed.
Osafo and colleagues [8] observed a 51 % prevalence of
CKD in patients with coexistent diabetes and hyperten-
sion, based on data from 712 participants in a multicen-
ter study in Accra, Ghana, and we observed 74 %
prevalence of CKD in our participants. Since their use of
the MDRD formula would have biased their findings
towards a greater incidence of CKD, it is possible that the
prevalence is truly higher in this group in Ghana.
Good blood pressure control and ACE inhibitors are
known to have a reno-protective effect, particularly in
people with albuminuria [16]. In our study, 30 % overall,
11.1 % of people with diabetes and hypertension, 9.2 %
of people with albuminuria and hypertension received
ACE inhibitor therapy. We are unable to determine from
our study to what extent this relatively low prevalence
represents true contraindications or previous adverse ef-
fects, or whether this is a possible missed treatment op-
portunity that results from the economic costs of the
drug (most of which are borne by the patients) or a
Table 4 Multivariable associations of clinical variables with CKD
in high-risk population
Variable OR (95 % CI) P-value
Gender
Malea Referent
Female 1.63 (0.82–3.24) 0.167
Age group
<40a Referent
40–49 0.88 (0.07–10.46) 0.921
50–59 2.16 (0.24–19.75) 0.496
60–69 2.41 (0.27–21.67) 0.433
≥70 2.80 (0.30–26.42) 0.369
Condition
HPTa Referent
DM 1.33 (0.65–2.71) 0.442
DM/HPT 10.32 (3.43–31.09) 0.000
BMI n (%)
Underweighta Referent
Normal 0.14 (0.01–1.47) 0.102
Overweight 0.14 (0.01–1.45) 0.1
Obese 0.13 (0.01–1.31) 0.083
Duration on medication
<5a Referent
5–10 1.01 (0.54–1.87) 0.989
>10 8.96 (1.74–46.10) 0.009
Diabetes medication
Non-diabetics Referent
Insulin 1.10 (0.48–2.55) 0.818
OHA 0.541 (0.28–1.05) 0.069
Anti-hypertensive medication
Non-hypertensive Referent
ACE-I 0.55 (0.21–1.45) 0.225
β-blocker 0.51 (0.22–1.20) 0.124
arefers to the referent
Table 3 Prevalence of albuminuria and estimated glomerular
filtration rate (eGFR) stratified by clinical conditions
Condition uPCR
(<3 mg/mmol) (3–30 mg/mmol) (>30 mg/mmol)
Hypertension
G1 15 (23) 1 (2) 0 (0)
G2 36 (55) 2 (3) 1 (2)
G3a 1 (2) 0 (0) 0 (0)
G3b 0 (0) 4 (6) 1 (2)
G4 0 (0) 3 (5) 1 (2)
Diabetes
G1 38 (32) 1 (1) 0 (0)
G2 50 (42) 4 (3) 0 (0)
G3a 11 (9) 4 (3) 0 (0)
G3b 3 (3) 6 (5) 0 (0)
G4 0 (0) 3 (3) 0 (0)
Hypertension and diabetes
G1 4 (17) 1 (4) 0 (0)
G2 2 (9) 3 (13) 0 (0)
G3a 0 (0) 3 (13) 0 (0)
G3b 1 (4) 3 (13) 0 (0)
G4 0 (0) 5 (22) 1 (4)
Each column shows n (% within diagnosis)
No patient had G5 eGFR; G1 = eGFR ≥90 G2 = eGFR 60–89, G3a = eGFR 45–59,
G3b = eGFR 30–44, G4 = eGFR 15–29
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reluctance on the part of physicians to prescribe ACE in-
hibitors without access to repeated monitoring of renal
function (laboratory tests are paid for by the patient).
Our study has several limitations. First our findings
cannot be generalized to other low income and low re-
source countries because it was not community based
and was conducted within a population at risk of de-
veloping CKD with genetic and cultural differences. Fur-
ther, there may be differences in the practices that lead
to a patient being identified as having hypertension or
diabetes, and differences in access to treatments for, and
monitoring of those conditions. The study was con-
ducted in the Sekondi-Takoradi metropolis. It is likely
that there would be significant variation in prevalence
rates in other urban and rural towns in the Western
region and across Ghana as a whole. This study is also
limited by the small sample size, use of the single meas-
urement of serum creatinine (whereas to truly fulfill def-
initions of CKD, two measurements at least 3 months
apart are needed), and by our lack of standardization of
serum creatinine to isotope mass dilution spectropho-
tometry (IMDS). Third, although the CKD-EPI eGFR
equation has been used in previous studies in this popu-
lation [8, 18, 19] it has not been validated for use in the
black Ghanaian population. Strengths of our study are the
consecutive sampling and completeness of data collection.
Conclusion
CKD was detected among 30 % of this high-risk popula-
tion. Further research is needed into optimal approaches
to screening and treatment, including research on the
effects of lowering economic barriers to known effective
treatments. This is particularly important in resource-
constrained practice settings such as ours, because the
impact of the development of end-stage renal disease
when dialysis cannot be provided is so much greater.
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